Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × 177Lu-octreotate × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Cisplatin 598 Carboplatin 497 Paclitaxel 481 Cyclophosphamide 443 Radiotherapy 440 Docetaxel 405 Fluorouracil 373 Gemcitabine 356 Doxorubicin 337 Capecitabine 307 Dexamethasone 276 Oxaliplatin 239 Vincristine 231 pembrolizumab 228 Leucovorin 227 Etoposide 225 Bevacizumab 225 Rituximab 204 Prednisone 193 Pemetrexed 178 Cytarabine 176 Drug Therapy 167 Trastuzumab 146 Methotrexate 146 Irinotecan 136 Lenalidomide 120 Filgrastim 115 Nivolumab 111 Chemotherapy, Adjuvant 109 Tamoxifen 105

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01860742 2016-04-05

CASTOR

Jules Bordet Institute

Phase 3 Withdrawn

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡